Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13050546 | 1.00 | PKM (0.47) | PKMALDH1A1POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL7054837 | 0.84 | MMP13 (0.38) | ALDH1A1POLB | |
| SCHEMBL7056601 | 0.81 | MMP13 (0.37) | ALDH1A1POLB | |
| SCHEMBL7058451 | 0.81 | MMP13 (0.39) | ALDH1A1POLB | |
| SCHEMBL7059791 | 0.80 | MMP13 (0.41) | ALDH1A1POLB | |
| SCHEMBL13264583 | 0.79 | PKM (0.39) | PKMALDH1A1POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL1381814 | 0.79 | POLB (0.53) | PKMALDH1A1POLBSMN1; SMN2RAB9A | |
| SCHEMBL7057498 | 0.78 | MMP13 (0.48) | — | |
| SCHEMBL1383019 | 0.78 | MMP1 (0.49) | PKMALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL4038593 | 0.74 | ALDH1A1 (0.51) | PKMALDH1A1POLBSMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946227-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20130143893-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2013-06-06 | — | — | US | disclosed |
| EP-1542993-B1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20100305137-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-7754722-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20060223813-A1 | Piperazine Derivatives and Methods of Use | MERCK SERONO SA (CH) | 2006-10-05 | — | — | US | disclosed |
| EP-1542993-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | Applied Research Systems ARS Holding N.V. (AN) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004031182-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305137-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | CATSPER1, NASP, HDAC5 | PKM 1422/4885ALDH1A1 568/4885POLB 1669/4885 |
| US-20130143893-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | CATSPER1, NASP, HDAC5 | PKM 1422/4885ALDH1A1 568/4885POLB 1669/4885 |
| US-20060223813-A1 | Piperazine Derivatives and Methods of Use | CATSPER1, H1-5, GNRHR | PKM 2156/4885ALDH1A1 1182/4885POLB 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.